Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease von Schormair, B., Kemlink, D., Mollenhauer, B., Fiala, O., Machetanz, G., Roth, J., Berutti, R., Strom, T.M., Haslinger, B., Trenkwalder, C., Zahorakova, D., Martasek, P., Ruzicka, E., Winkelmann, J.

Volltext

NGAL, albumin and cystatin C during cisplatin therapy von Florova, B., Rajdl, D., Racek, J., Fiala, O., Matejka, V. M., Trefil, L.

Volltext

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib von Fiala, O, Pesek, M, Finek, J, Racek, J, Minarik, M, Benesova, L, Bortlicek, Z, Sorejs, O, Kucera, R, Topolcan, O

Volltext

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis von Buchler, T, Fiala, O, Veskrnova, V, Chloupkova, R, Poprach, A, Kiss, I, Kopeckova, K, Dusek, L, Slavicek, L, Kohoutek, M, Finek, J, Svoboda, M, Dvorak, J, Petruzelka, L B, Melichar, B

Volltext

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis von Kopeckova, K, Chloupkova, R, Melichar, B, Linke, Z, Petruzelka, L B, Finek, J, Fiala, O, Tomasek, J, Kiss, I, Prausova, J, Buchler, T

Volltext

2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data von Melichar, B, Poprach, A, Kubáčková, K, Fiala, O, Studentová, H, Holečková, P, Lakomý, R, Hejduk, K, Vyzula, R, Büchler, T

Volltext

Smart Institutions for Smart Cities von Wiesmeth, H, Fiala, O, Stegareva, E, Häckl, D, Weinhold, I

Volltext

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed von Fiala, O, Hosek, P, Pesek, M, Finek, J, Racek, J, Buchler, T, Poprach, A, Hejduk, K, Chloupkova, R, Sorejs, O, Ecksteinova, M, Vitovec, M, Cizkova, K, Kucera, R, Topolcan, O

Volltext

73P GENE MUTATIONS IN SQUAMOUS-CELL NSCLC: INSIGNIFICANCE OF EGFR, KRAS AND PIK3CA MUTATIONS IN PREDICTION OF EGFR-TKI TREATMENT EFFICACY von Fiala, O, Pesek, M, Finek, J, Benesova, L, Bortlicek, Z, Minarik, M

Volltext

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice von Fiala, O, Pesek, M, Finek, J, Krejci, J, Ricar, J, Bortlicek, Z, Benesova, L, Minarik, M

Volltext

119P The study of differentially expressed genes in metachronous colorectal liver metastasis samples using RNA sequencing von Rao, B.H., Seberova, K., Liška, V., Vyčítal, O., Fiala, O., Hlaváč, V., Souček, P.

Volltext

9093 POSTER The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors von Fiala, O, Pesek, M, Benesova, L, Belsanova, B, Minarik, M

Volltext

Estimation of potential interactive effects of chemical mixtures von Borská, L., Fiala, Z., Vyskocil, A., Lemay, F., Fiala, O., Kremlacek, J., Borsky, T., Krajak, V.

Volltext

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC von Fiala, O, Pesek, M, Finek, J, Benesova, L, Bortlicek, Z, Minarik, M

Volltext

9074 POSTER DNA Hypermethylation in Progressive Advanced Non Small Cell Lung Cancer von Pesek, M, Benesova, L, Bruha, F, Mukasnabl, P, Kopeckova, M, Bittenglova, R, Fiala, O, Krakorova, G, Sefrna, F, Minarik, M

Volltext

Erlotinib in the treatment of advanced squamous cell NSCLC von Fiala, O, Pesek, M, Finek, J, Krejci, J, Havel, L, Hrnciarik, M, Salajka, F, Bortlicek, Z, Benesova, L, Minarik, M

Volltext

1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) von Catalano, M., Roviello, G., Buti, S., Massari, F., Li, H., Park, S.H., Grande, E., Kucharz, J., Fiala, O., Poprach, A., Buchler, T., Seront, E., Ansari, J., Myint, Z.W., Bhuva, D.M., Bamias, A., Ghosn, M., Andrey, S., Santoni, M., Santini, D.

Volltext

Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study von Mollica, V., Massari, F., Fiala, O., Kucharz, J., Molina-Cerrillo, J., Seront, E., Bourlon, M.T., Pichler, R., Myint, Z.W., Kanesvaran, R., Marchetti, A., Rosellini, M., Rescigno, P., de Liano, A.G., Zakopoulou, R., Buti, S., Porta, C., Grande, E., Santoni, M.

Volltext

A0839 - Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study von Mollica, V., Massari, F., Fiala, O., Kucharz, J., Molina-Cerrillo, J., Seront, E., Bourlon, M.T., Pichler, R., Myint, Z.W., Kanesvaran, R., Marchetti, A., Rosellini, M., Rescigno, P., de Liano, A.G., Zakopoulou, R., Buti, S., Porta, C., Grande, E., Santoni, M.

Volltext

Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC) von Finek, J., Poprach, A., Melichar, B., Kopecky, J., Zemanova, M., Buchler, T., Kopeckova, K., Mlcoch, T., Dolezal, T., Fiala, O.

Volltext